---

Prevalence of DFU among diabetic patients and its management

---

Original Article

Author Details : Amit Kumar*, S. Sai Prasanna, R. Charishma, R. Satya Divya, R. V. V. Sowjanya

Volume : 8, Issue : 4, Year : 2021

Article Page : 258-262

https://doi.org/10.18231/j.ijpp.2021.046

Suggest article by email

Get Permission

---

Abstract

Objective: To study the prevalence of DFU among diabetic patients and the management of DFU among diabetic patients.
Design: Prospective observational study.
Materials and Methods: The study was conducted in inpatients with diabetes of all departments and inpatients with diabetic foot ulcer (DFU) of surgical department of age 20 to 80 of both genders with sample size 150 were included from September 2019 to march 2020.
Results: The prevalence of DFU among diabetic patients was 16%. Among them more diabetic cases were seen in age group of 50-59 and DFU in 40-49 and More diabetic cases are observed in male compared to female. DFU observed equally and the most common causative organism for DFU was staphylococcus aureus followed by proteus species, klebsiella and pseudomonas aeruginosa and more cases of DFU were noticed in diabetic patients with duration of 6-10 years. As the main cause of DFU is infection the primary treatment is anti microbial therapy and the most prescribed class of antibiotics is cephalosporins followed by nitroimidazoles, penicillins, oxazolidinones, lincosamides etc. surgical procedures like debridement, amputation and sometimes both were done in 9,14,1 patients respectively.
Conclusion: Our study revealed the information regarding the prevalence of DFU among diabetic patients is due to lack of knowledge and uncontrolled diabetes may develop poor circulation which leads to wound that may heal slowly which leads to DFU.

Keywords: DFU, Diabetes, Debridement, Amputation, Antimicrobial Therapy, Antibiotics

How to cite : Kumar A, Prasanna S S, Charishma R, Divya R S, Sowjanya R V V, Prevalence of DFU among diabetic patients and its management. Indian J Pharm Pharmacol 2021;8(4):258-262

This is an Open Access (OA) journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.